Torcetrapib's Silver Lining
This article was originally published in RPM Report
Executive Summary
What looks like bad news for the future of the CEPT inhibitor class of HDL-raising drugs may have a hidden silver lining for pharmaceutical companies interested in advancing the use of imaging as a clinical trial endpoint.
You may also be interested in...
Imaging Standards for Clinical Trials: A Picture Worth 1,000 Guidance Documents
FDA is signaling its commitment to validating surrogate endpoints by agreeing to set standards on the use of imaging techniques in clinical trials. But industry will have to wait for a definitive answer: the document isn't slated for released until 2011.
Imaging Standards for Clinical Trials: A Picture Worth 1,000 Guidance Documents
FDA is signaling its commitment to validating surrogate endpoints by agreeing to set standards on the use of imaging techniques in clinical trials. But industry will have to wait for a definitive answer: the document isn't slated for released until 2011.
Abbott Rides High After Torcetrapib Collapse: Is Everything Old New Again?
The end of torcetrapib was bad news for Pfizer, and could be a death knell for the entire CETP inhibitor class. But it also makes Abbott's acquisition of Kos look prescient. Wall Street is taking notice.